A Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug Product in AIS Subjects
Status:
Not yet recruiting
Trial end date:
2024-03-31
Target enrollment:
Participant gender:
Summary
This is a phase II, double-blind, randomized, placebo-controlled study to evaluate the safety
and efficacy of multiple doses of LT3001 drug product in subjects with acute ischemic stroke
(AIS)